PTK2 and non-small cell lung carcinoma: In conclusion, our results provide strong evidence that elevated FAK levels are a key driver of acquired EGFR-TKI resistance and can serve as a biomarker for poor prognosis in NSCLC patients treated with EGFR-TKIs.